Related references
Note: Only part of the references are listed.Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas
Sarah Larkin et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
Novel pathway for somatostatin analogs in patients with acromegaly
Monica R. Gadelha et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2013)
Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression
Leandro Kasuki et al.
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA (2012)
Temozolomide in aggressive pituitary adenomas and carcinomas
Leon D. Ortiz et al.
CLINICS (2012)
AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression
Leandro Kasuki et al.
ENDOCRINE-RELATED CANCER (2012)
Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway
Harvinder S. Chahal et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Biomarkers of aggressive pituitary adenomas
Ozgur Mete et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2012)
Clinical implications of growth hormone-secreting tumor subtypes
Katja Kiseljak-Vassiliades et al.
ENDOCRINE (2012)
Efficacy and Safety of Radiotherapy in Acromegaly
Baldomero Gonzalez et al.
ARCHIVES OF MEDICAL RESEARCH (2011)
Treatment of Pituitary Neoplasms With Temozolomide A Review
Luis V. Syro et al.
CANCER (2011)
Resistance to Somatostatin Analogs in Acromegaly
Annamaria Colao et al.
ENDOCRINE REVIEWS (2011)
Therapy of aggressive pituitary tumors
Annamaria Colao et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome
John A. Jane et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Excess mortality for patients with residual disease following resection of pituitary adenomas
Michael E. Sughrue et al.
PITUITARY (2011)
Management of acromegaly in Latin America: expert panel recommendations
Ariel Barkan et al.
PITUITARY (2010)
SURGICAL REINTERVENTION IN ACROMEGALY: IS IT STILL WORTH TRYING?
Ana Laura Espinosa de los Monteros et al.
ENDOCRINE PRACTICE (2009)
Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients
S. J. C. M. M. Neggers et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Guidelines for Acromegaly Management: An Update
S. Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
KI-67 IN PITUITARY NEOPLASMS: A REVIEW-PART I
Fateme Salehi et al.
NEUROSURGERY (2009)
Management of aggressive pituitary adenomas: current treatment strategies
Michael Buchfelder
PITUITARY (2009)
Surgical Results of Growth Hormone-Secreting Pituitary Adenoma
Min-Su Kim et al.
JOURNAL OF KOREAN NEUROSURGICAL SOCIETY (2009)
Clinicopathological features of growth hormone-producing pituitary adenomas: Difference among various types defined by cytokeratin distribution pattern including a transitional form
Abdulkader Obari et al.
ENDOCRINE PATHOLOGY (2008)
Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas
Roger Gejman et al.
HUMAN PATHOLOGY (2008)
Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Raquel S. Jallad et al.
CLINICAL ENDOCRINOLOGY (2007)
Treatment of acromegaly: is there still a place for radiotherapy?
Raquel S. Jallad et al.
PITUITARY (2007)
Pathohistological classification of pituitary tumors:: 10 years of experience with the German Pituitary Tumor Registry
Wolfgang Saeger et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on lGF-I levels, tumor mass, hypertension and glucose tolerance
A Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Predictive markers of pituitary adenoma behavior
George Kontogeorgos
NEUROENDOCRINOLOGY (2006)
The 2004 World Health Organization classification of pituitary tumors: What is new?
M Al-Shraim et al.
ACTA NEUROPATHOLOGICA (2006)
Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist
JOL Jorgensen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Predictors and rates of treatment-resistant tumor growth in acromegaly
GM Besser et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
J Feenstra et al.
LANCET (2005)
Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: outcome analysis in a series of 125 patients
V Esposito et al.
NEUROLOGICAL SCIENCES (2004)
Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espahol de Acromegalia, REA)
A Mestrón et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature
G Minniti et al.
ENDOCRINE-RELATED CANCER (2003)
Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly
C Beauregard et al.
CLINICAL ENDOCRINOLOGY (2003)
The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery
BP Meij et al.
JOURNAL OF NEUROSURGERY (2002)
Share Paper
